PMID- 24138719
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 20
IP  - 24
DP  - 2014
TI  - Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days 
      night'.
PG  - 3958-72
AB  - The discovery of specific molecular alterations (i.e. EGFR activating mutations, 
      EML4/ALK translocation, ROS1 rearrangements) in a selected population of patients 
      affected by non small cell lung cancer (NSCLC) translated into effective 
      treatments for this small but well defined fraction of patients, driven by the 
      use of predictive biomarkers of efficacy for targeted agents. Unfortunately, the 
      same reliable predictive biomarkers are lacking for anti-angiogenic drugs. 
      Angiogenesis plays a major role in the progression of NSCLC, however, 
      anti-angiogenic agents provided a minimal, although significant, clinical benefit 
      in unselected populations, burdened by a not negligible toxicities. In this 
      context, no validated angiogenic factor or other molecular biomarker of 
      angiogenesis can reliably predict clinical outcome, sensitivity, early response 
      or resistance to any of the investigated anti-angiogenic therapies currently 
      used. Moreover, the available clinical data are prevalently retrospective, 
      underpowered, and, in many cases, contradictory, thus underscoring that the 
      understanding of the complex architecture of angiogenic signaling is still 
      incomplete. We here review the currently available studies on the effect of 
      anti-angiogenic drugs in NSCLC, with a particular focus on bio-molecular factors 
      that are regarded as potential predictors of treatment efficacy.
FAU - Pilotto, Sara
AU  - Pilotto S
FAU - Bonomi, Maria
AU  - Bonomi M
FAU - Massari, Francesco
AU  - Massari F
FAU - Milella, Michele
AU  - Milella M
FAU - Ciuffreda, Ludovica
AU  - Ciuffreda L
FAU - Brunelli, Matteo
AU  - Brunelli M
FAU - Fassan, Matteo
AU  - Fassan M
FAU - Chilosi, Marco
AU  - Chilosi M
FAU - Scarpa, Aldo
AU  - Scarpa A
FAU - Tortora, Giampaolo
AU  - Tortora G
FAU - Bria, Emilio
AU  - Bria E
AD  - Medical Oncology dU, Policlinico 'G.B. Rossi', University of Verona, P.zza L.A. 
      Scuro 1, 37134, Verona, Italy. emiliobria@yahoo.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Angiogenesis Inhibitors/*pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Biomarkers, Tumor/antagonists & inhibitors/genetics/*metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Neovascularization, Pathologic/drug therapy/genetics
EDAT- 2013/10/22 06:00
MHDA- 2015/03/31 06:00
CRDT- 2013/10/22 06:00
PHST- 2013/09/18 00:00 [received]
PHST- 2013/10/28 00:00 [accepted]
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - CPD-EPUB-56749 [pii]
AID - 10.2174/13816128113196660757 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2014;20(24):3958-72. doi: 10.2174/13816128113196660757.